Detailed Narrative
Temporary Delay in Semaglutide Injection Commercial Supply
Dr. Reddy's Laboratories announced a temporary delay in the commercial supply of its Semaglutide injection. This delay stems from an impurity issue identified during the scale-up of the synthetic API manufacturing process at its facility. While the API itself met specifications, one of the impurities was found to be out of specifications upon testing of the finished drug product, indicating degradation during formulation.
Resolution Timeline and Process Adjustments
The company is undertaking a thorough investigation to determine the root cause and implement necessary process improvements. Management expects to make adjustments to the API process and complete three validation batches by around September 2026. Following successful validation, commercial API scale is anticipated to reach OneSource during October, with actual market supply resuming by late October or early November 2026.
Revised Supply Target and No Patient Safety Concerns
Despite the delay, Dr. Reddy's remains confident in supplying 6-7 million Semaglutide injection pens between Q3 and Q4 of FY27. The company emphasized that there is no patient safety impact associated with products already supplied to the market, and no product recall is required. The issue pertains only to scale-up batches that never reached the market.
Unaffected Products and Regulatory Filings
The company confirmed that its manufacturing facilities continue to operate in compliance with cGMP and global regulatory requirements. There is no impact on the product's existing global regulatory filings, whether approved or under review. Additionally, the supply of Semaglutide oral tablets remains unaffected as they utilize a different API source.
Financial Implications and Partnership Outlook
While the delay will result in missing certain sales quantities, management stated that the overall 20%+ EBITDA margin target remains unchanged, though there will be a short-term downside. The company does not anticipate penalties for the supply disruption, but some arrangements with partners might require renegotiation. Dr. Reddy's is committed to long-term partnerships with OneSource and is also qualifying a backup API supplier, though this will take approximately one year due to pre-approval supplement requirements.